Faculty, Staff and Student Publications
Publication Date
6-4-2025
Journal
The Oncologist
DOI
10.1093/oncolo/oyaf152
PMID
40536268
PMCID
PMC12204399
PubMedCentral® Posted Date
6-19-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Precision oncology has transformed the treatment landscape for patients with advanced solid tumors. Tumor-agnostic therapies, those that have been approved based on genetic mutations or biomarkers across tumor histology types, are important examples of how the implementation of precision oncology can expand therapeutic options for patients, especially those with rare cancer types and treatment-refractory disease. In this review, we first discuss how advances in next-generation sequencing and molecular profiling have enabled the identification of shared actionable alterations. Subsequently, we explore the current landscape of tumor-agnostic therapies that have received approval from the Food and Drug Administration. We discuss the strengths and limitations of these therapies and evaluate the clinical trial data leading to their approval. In addition, we detail updated results from these clinical trials and additional observational studies reported after the approval. Several factors such as tumor histology, specific alteration types, and the presence of co-alterations are associated with the efficacy of these therapies. Also, challenges remain in understanding resistance mechanisms and predicting response. Looking ahead, we discuss how improved diagnostic tools, novel experimental strategies, and innovative trial designs may further advance the field of precision oncology and improve therapeutic options for patients.
Keywords
Humans, Precision Medicine, Neoplasms, Medical Oncology, Biomarkers, Tumor, High-Throughput Nucleotide Sequencing, precision oncology, tumor-agnostic therapy, molecular profiling, targeted therapy, biomarker-driven treatment
Published Open-Access
yes
Recommended Citation
Nakul M Shah and Funda Meric-Bernstam, "The Present and Future of Precision Oncology and Tumor-Agnostic Therapeutic Approaches" (2025). Faculty, Staff and Student Publications. 4825.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4825
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons